Recently, the Focused Ultrasound Foundation highlighted RebrAIn’s success in obtaining its second FDA 510(k) approval – which extends the capabilities of its OptimMRI software to include new machine learning models for lesioning treatment of Essential Tremor, thereby enhancing precision in neurosurgical targeting – and implicitly praised its Medical Advisory Board (MAB).
Indeed, RebrAIn, a leader in AI-powered neurosurgical solutions, recently held the inaugural meeting of its MAB focusing on guiding the company’s next steps in delivering cutting-edge AI solutions aimed at improving surgical outcomes.
The MAB is composed of globally recognized experts in neurology and neurosurgery:
- Ausaf Bari, MD, PhD (University of California Los Angeles)
- Rees Cosgrove, MD (Brigham and Women’s Hospital)
- Lain Hermes González, MD (Clínica Universidad)
- Joohi Jimenez-Shahed, MD (Mount Sinai)
- Michael Kinsman, MD (University of Kansas Hospital)
- Shayan Moosa, MD (University of Virginia)
- Charles Munyon, MD (Charlotte Novant Health)
- Jean Régis, MD (Assistance Publique – Hôpitaux de Marseille)
- John Rolston, MD, PhD (Brigham and Women’s Hospital)
“We are honored to receive this recognition from the Focused Ultrasound Foundation, as it reflects the progress we have made in pushing the boundaries of AI in neurosurgical planning,” said David Caumartin, CEO of RebrAIn.
The collaboration between RebrAIn and its Medical Advisory Board will be essential in shaping the future of AI-assisted neurosurgical procedures, further refining our solutions, and pushing the limits of what is possible in neurosurgical care, ensuring that RebrAIn’s innovations are grounded in clinical realities and providing more personalized and precise treatments to patients worldwide.
Stay tuned for further updates as RebrAIn advances the future of brain disorder treatments through innovative AI technology.
Read the full article on the Focused Ultrasound Foundation’s webstie.
